Home > Healthcare & Medical Devices > Infant Phototherapy Market
Infant Phototherapy Market Size is expected to grow commendably between 2022 and 2028, due to the ability of this technique to lower the level of bilirubin in infants and function as an effective treatment against jaundice and hyperbilirubinemia. Furthermore, the introduction of lightweight and compact LED infant phototherapy light systems to treat neonatal unconjugated hyperbilirubinemia will also add impetus to industry outlook in the coming years. Phototherapy refers to a medical treatment in which artificial or natural lights, including fluorescent light bulbs, sunlight, halogen lights, and LEDs, are used to improve health conditions. It is increasingly adopted to treat newborn jaundice by lowering bilirubin pigments in their blood via photo-oxidation.
Rising prevalence of neonatal jaundice among preterm babies is one of the major trends characterizing the infant phototherapy market dynamics through 2028. Babies born prior to 37 weeks of pregnancy have high chances of developing jaundice owing to their immature liver, causing an excess of bilirubin. Factors such as these, alongside the strong focus on the development of innovative devices to assess bilirubin levels in jaundiced babies, will also proliferate the adoption of infant jaundice phototherapy. However, the potential adverse effects of phototherapy in infants, like overheating and dehydration, may hinder the market share during the forecast timeline.
Considering technique, the fiberoptic phototherapy segment will account for an appreciable share in the market by 2028. Growth from this segment is a result of the emergence of home phototherapy as an alternative to in-hospital treatment for healthy-term newborns. These fiberoptic devices deliver light from phototherapy lamps to Biliblanket, a fiberoptic blanket, which is commonly used for home therapy of infants, hence amplifying the segment expansion in the coming years.
The Middle East and Africa infant phototherapy market is slated to amass considerable profits by 2028. This is given the high burden of morbidity and mortality of severe hyperbilirubinemia across the Sub-Saharan African countries. According to the General Authority for Statistics mid-2020 report, over 25,000 babies are prematurely born in Saudi Arabia each year. This, coupled with the increased emphasis of the governments to enhance the healthcare sector, will stimulate the requirement of infant phototherapy equipment across the region.
The competitive landscape of the market comprises companies such as Wellton Healthcare, Neotech Medical Systems Pvt. Ltd., Zhengzhou Dison Instrument and Meter Co., Ltd., Ningbo David Medical Device Co. Ltd., Phoenix Medical Systems Pvt. Ltd., Equalize Health (formerly D-Rev), Signify Holding B.V., Natus Medical Incorporated, AVI Healthcare, General Electric Company, and Ibis Medical. Strategic product launches, collaborations, acquisitions, and business expansions are among the initiatives being undertaken by these firms to reinforce their presence in the global market.
The novel coronavirus pandemic and its associated restrictions have affected both the quality and provision of neonatal care over the past year. Due to the restrictions imposed to limit the parental presence at hospitals during the pandemic, a reduction in the number of care-seeking parents as well as the lack of guidelines for preterm babies and infants with low birthweight were observed. Despite these setbacks, the substantial impact of the virus on infant wellbeing may aid industry recovery over the foreseeable future. SARS-CoV-2 infection during pregnancy has been linked to heightened risks of preterm birth, which could boost the need for premature infant phototherapy to treat jaundice, a common condition in premature babies.
Market, by Technique
Market, by Product Type
Market, by Light Source
Market, by End-Use
The above information is provided for the following regions and countries: